The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting study proposals to evaluate candidate cellular therapies to treat radiation-induced injuries in appropriate in vivo models when administered 24 hours or [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement (BAA) expected to be formally released on February 21, 2017. The BAA [Read more]
The Defense Threat Reduction Agency recently updated its Broad Agency Announcement (BAA) supporting Fundamental Research to Counter Weapons of Mass Destruction. Issued in March 2015, the BAA is effective through 2024 or [Read more]
Pluristem Therapeutics on Dec. 6 announced a milestone in its development program for PLX-R18, which is being evaluated as a medical countermeasure in the treatment of the hematologic components of Acute Radiation [Read more]
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) is purchasing two medical products to treat injuries to bone marrow in victims of [Read more]
The CBRNe Summit Asia 2016 conference will be held December 5-7, 2016 in Hanoi, Vietnam. This event features stakeholder presentations on all aspects of CBRNe defense, allowing you to develop your understanding [Read more]
To help save as many people as possible in the event of a large-scale nuclear or radiological emergency, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for [Read more]
A new Department of Defense Broad Agency Announcement (BAA) released this week seeks proposals for extramural research supporting both military and civilian medical practice and knowledge. The U.S. Army Medical Research Acquisition [Read more]
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, recently reported financial results and summarized corporate and clinical developments for its fiscal year ended June 30, 2016. “Over the past [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Countermeasures Development Program supports extramural research to develop safe and effective medical countermeasures for clinical use under emergency situations. NIAID today announced [Read more]
© 2017 Global Biodefense